A single cysteine residue in vimentin regulates long non-coding RNA XIST to suppress epithelial-mesenchymal transition and stemness in breast cancer
Curation statements for this article:-
Curated by eLife
eLife Assessment
This study presents a valuable finding that C238 in vimentin regulates long non-coding RNA XIST to suppress EMT and thereby Xist may be a therapeutic target in breast cancer. The evidence supporting the claims of the authors is solid, although the improvement of data visibility and presentation would have strengthened the study. The work will be of interest to scientists working in the field of BCs.
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (eLife)
Abstract
Vimentin is a type III intermediate filament (IF) protein, that is induced in a large number of solid tumours. A single cysteine at position 328 in vimentin plays a crucial role in assembly, organisation and stability of IFs. However, its exact function during epithelial mesenchymal transition (EMT) and cancer progression has not been investigated. To investigate this, we have transduced wildtype (WT) and C328S vimentin separately in MCF-7 cells that lack endogenous vimentin. The expression of C328-VIM impacted vimentin-actin interactions and induced EMT-like features that include enhanced cell proliferation, migration, invasion accompanied by reduced cell adhesion when compared to the wildtype cells. Functional transcriptomic studies confirmed the upregulation of EMT and mesenchymal markers, downregulation of epithelial markers as well as acquisition of signatures associated with cancer stemness ( CD56, Oct4, PROCR and CD49f ) thus transforming MCF-7 cells from oestrogen positive to triple reduced ( ESR1, PGR, and HER2 ) status. We also observed a stark increase in the expression of long non-coding RNA, XIST in MCF-7 cells expressing C328-VIM. Targeting the mutant vimentin or XIST by RNA interference partially reversed the phenotypes in C328-VIM expressing MCF-7 cells. Furthermore, introduction of C328-VIM cells into nude mice promoted tumour growth by increasing cancer stemness in an oestrogen independent manner. Altogether, our studies provide insight into how cysteine 328 in vimentin dictates mechano-transduction signals to remodel actin cytoskeleton and protect against EMT and cancer growth via modulating lncRNA XIST . Therefore, targeting vimentin and/or XIST via RNA interference should be a promising therapeutic strategy for breast cancer treatment.
Article activity feed
-
-
-
eLife Assessment
This study presents a valuable finding that C238 in vimentin regulates long non-coding RNA XIST to suppress EMT and thereby Xist may be a therapeutic target in breast cancer. The evidence supporting the claims of the authors is solid, although the improvement of data visibility and presentation would have strengthened the study. The work will be of interest to scientists working in the field of BCs.
-
Reviewer #1 (Public review):
Summary, and Strengths:
The authors and their team have investigated the role of Vimentin Cysteine 328 in epithelial-mesenchymal transition (EMT) and tumorigenesis. Vimentin is a type III intermediate filament, and cysteine 328 is a crucial site for interactions between vimentin and actin. These interactions can significantly influence cell movement, proliferation, and invasion. The team has specifically examined how Vimentin Cysteine 328 affects cancer cell proliferation, the acquisition of stemness markers, and the upregulation of the non-coding RNA XIST. Additionally, functional assays were conducted using both wild-type (WT) and Vimentin Cysteine 328 mutant cells to demonstrate their effects on invasion, EMT, and cancer progression. Overall, the data supports the essential role of Vimentin Cysteine 328 …
Reviewer #1 (Public review):
Summary, and Strengths:
The authors and their team have investigated the role of Vimentin Cysteine 328 in epithelial-mesenchymal transition (EMT) and tumorigenesis. Vimentin is a type III intermediate filament, and cysteine 328 is a crucial site for interactions between vimentin and actin. These interactions can significantly influence cell movement, proliferation, and invasion. The team has specifically examined how Vimentin Cysteine 328 affects cancer cell proliferation, the acquisition of stemness markers, and the upregulation of the non-coding RNA XIST. Additionally, functional assays were conducted using both wild-type (WT) and Vimentin Cysteine 328 mutant cells to demonstrate their effects on invasion, EMT, and cancer progression. Overall, the data supports the essential role of Vimentin Cysteine 328 in regulating EMT, cancer stemness, and tumor progression. Overall, the data and its interpretation are on point and support the hypothesis. I believe the manuscript has great potential.
Weaknesses:
Minor issues are related to the visibility and data representation in Figures 2E and 3 A-F.
-
Reviewer #2 (Public review):
The aim of the investigation was to find out more about the mechanism(s) by which the structural protein vimentin can facilitate the epithelial-mesenchymal transition in breast cancer cells.
The authors focussed on a key amino acid of vimentin, C238, its role in the interaction between vimentin and actin microfilaments, and the downstream molecular and cellular consequences. They model the binding between vimentin and actin in silico to demonstrate the potential involvement of C238, but the outcome is described vaguely. The phenotype of a non-metastatic breast cancer cell line MCF7, which doesn't express vimentin, could be changed to a metastatic phenotype when mutant C238S vimentin, but not wild-type vimentin, was expressed in the cells. Expression of vimentin was confirmed at the level of mRNA, protein, …
Reviewer #2 (Public review):
The aim of the investigation was to find out more about the mechanism(s) by which the structural protein vimentin can facilitate the epithelial-mesenchymal transition in breast cancer cells.
The authors focussed on a key amino acid of vimentin, C238, its role in the interaction between vimentin and actin microfilaments, and the downstream molecular and cellular consequences. They model the binding between vimentin and actin in silico to demonstrate the potential involvement of C238, but the outcome is described vaguely. The phenotype of a non-metastatic breast cancer cell line MCF7, which doesn't express vimentin, could be changed to a metastatic phenotype when mutant C238S vimentin, but not wild-type vimentin, was expressed in the cells. Expression of vimentin was confirmed at the level of mRNA, protein, and microscopically. Patterns of expression of vimentin and actin reflected the distinct morphology of the two cell lines. Phenotypic changes were assessed through assay of cell adhesion, proliferation, migration, and morphology and were consistent with greater metastatic potential in the C238S MCF7 cells. Changes in the transcriptome of MCF7 cells expressing wild-type and C238S vimentins were compared and expression of Xist long ncRNA was found to be the transcript most markedly increased in the metastatic cells expressing C238S vimentin. Moreover changes in expression of many other genes in the C238S cells are consistent with an epithelial mesenchymal transition. Tumourigenic potential of MCF7 cells carrying C238S but not wild-type, vimentin was confirmed by inoculation of cells into nude mice. This assay is a measure of the stem-cell quality of the cells and not a measure of metastasis. It does demonstrate phenotypic changes that could be linked to metastasis.
shRNA was used to down-regulate vimentin or Xist in the MCF7 C238S cells. The description of the data is limited in parts and data sets require careful scrutiny to understand the full picture. Down-regulation of vimentin reversed the morphological changes to some degree, but down-regulation of Xist didn't. Conversely, down-regulation of Xist inhibited cell growth, a sign of reversing metastatic potential, but down-regulation of vimentin had no effect on growth. Down-regulation of either did inhibit cell migration, another sign of metastatic reversal. The interpretation of this type of experiment is handicapped when full reversal of expression is not achieved, as was the case in this study.
Overall the study describes an intriguing model of metastasis that is worthy of further investigation, especially at the molecular level to unravel the connection between vimentin and metastasis. The identification of a potential role for Xist in metastasis, beyond its normal role in female cells to inactivate one of the X chromosomes, corroborates the work of others demonstrating increased levels in a variety of tumours in women and even in some tumours in men. It would be of great interest to see where in metastatic cells Xist is expressed and what it binds to.
-
-